Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05055128 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
A Phase 2 study of Erosive Esophagitis, sponsored by Cinclus Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
- 20
- Study locations
NCT05055128 is a Phase 2 study of Erosive Esophagitis that has completed, run by Cinclus Pharma. The registered enrollment target is 248 participants, above the 169-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05055128, a Phase 2 study of Erosive Esophagitis, has completed, sponsored by Cinclus Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.
Conditions Studied
Interventions
- DRUG Lansoprazole
- DRUG X842
- DRUG X842 Dummy
- DRUG Lansoprazole Dummy
Study Locations (20)
Other
- Medical Centre Asklepii - Dupnitsa
- Medical Center Medconsult Pleven - Pleven
- DCC-1 Sliven - Plovdiv
- MHAT "Kaspela" - Plovdiv
- Medical Center Prolet EOOD - Rousse
- Diagnostive Consultative Center-1 Sliven - Sliven
- Medical Center Hera - Gastroenterology office - Sliven
- 2-nd MHAT - Sofia
- Medical Center Excelsior - Sofia
- MHAT "Sveti Ivan Rilski" - Sofia - Sofia
- Medical Center Hera - Gastroenterology office - Sofia
- Medical Center New Rehabilitation Center EOOD - Stara Zagora
- Medical Center "Biomed 99" Ltd - Vidin
- Mhat "Hristo Botev" - Vratsa
- ResTrial GastroEndo s.r.o. - Prague
Sofia-Grad
- Medical Center Excelsior - Sofia
- DCC XIV Sofia - Sofia
- DCC XIV Sofia - Sofia
Florida
- Genesis Clinical Research - Tampa - Tampa
Adjara
- LTD"Brothers" - Batumi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05055128
The ClinicalTrials.gov registry entry for NCT05055128 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 6 other Erosive Esophagitis trials with a reported enrollment target (47% higher). The listed sponsor is Cinclus Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erosive Esophagitis appearing as the primary indexed condition, and to 4 interventions - of which Lansoprazole is the first listed.
NCT05055128 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Sofia-Grad, Florida.
Frequently Asked Questions
What is clinical trial NCT05055128 about?
NCT05055128 is a clinical study titled "A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole". This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment hea...
What is the current status of trial NCT05055128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2021-08-11. Estimated completion is 2022-09-01.
What conditions does trial NCT05055128 study?
This clinical trial studies the following conditions: Erosive Esophagitis.
What interventions are being tested in trial NCT05055128?
The interventions under investigation include: Lansoprazole (DRUG), X842 (DRUG), X842 Dummy (DRUG), Lansoprazole Dummy (DRUG).
Who is sponsoring clinical trial NCT05055128?
This trial is sponsored by Cinclus Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05055128 being conducted?
This trial has 20 study locations across Florida, Sofia-Grad, Adjara. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erosive Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
RECRUITING · Phase 2
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
RECRUITING · Phase 3
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
-
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
COMPLETED · Phase 4
-
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.